KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Long-Term Debt Repayments (2025)

Biocryst Pharmaceuticals' Long-Term Debt Repayments history spans 1 years, with the latest figure at $184.2 million for Q4 2025.

  • For Q4 2025, Long-Term Debt Repayments changed N/A year-over-year to $184.2 million; the TTM value through Dec 2025 reached $230.5 million, changed N/A, while the annual FY2025 figure was $300.0 million, N/A changed from the prior year.
  • Long-Term Debt Repayments reached $184.2 million in Q4 2025 per BCRX's latest filing, up from $46.3 million in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $184.2 million in Q4 2025 to a low of $46.3 million in Q3 2025.